The vaccine developed by the American firm Novavax against covid-19 has been shown to be safe and totally effective in patients considered “high risk” and with the main new variants of the virus.
According to a statement released Monday by the Maryland-based company, the preparation, still in phase 3 of study, has been shown to be 93% effective against the main virus variants currently circulating and to be 91% effective in high-risk patients.
NVX-CoV2373, the technical name for the recombinant nanoparticle protein-based vaccine, has met protection expectations in phase 3 trials, which have included a total of 29,960 patients from the United States and Mexico.
“Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines. These clinical results reinforce that NVX-CoV2373 is extremely effective and offers complete protection against moderate and severe COVID-19 infection, “said Stanley C. Erck, president and CEO of the firm.
“Novavax continues to work with a sense of urgency to complete our regulatory filings and deliver this vaccine, built on a well-known and proven platform, to a world that still has a great need for vaccines,” the executive said.
The company intends to apply for regulatory clearances in the third quarter this year, once the final stages of process qualification and assay validation necessary to meet US agency chemistry, manufacturing and controls requirements are completed.
Novavax could reach a manufacturing capacity of 100 million doses per month by the end of the third quarter of 2021 and 150 million doses per month by the end of the fourth quarter of 2021.
Gregory M. Glenn, Novavax President of Research and Development said the data “shows consistent and high levels of efficacy and reaffirms the vaccine’s ability to prevent COVID-19 amid the ongoing genetic evolution of the virus.”